Financials in USD. Standardized financial statements.
A compact view of how Black Diamond Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $70.00M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $325,000 | $0 | $437,000 | $0 | $0 | $0 | $47,000 | $44,000 | $24,000 |
| Gross Profit? | $69.67M | $0 | -$437,000 | $0 | $0 | $0 | -$47,000 | -$44,000 | -$24,000 |
| Gross Margin? | +99.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $49.80M | $78.78M | $86.02M | $92.83M | $126.87M | $69.57M | $29.33M | $8.90M | $4.12M |
| Operating Income? | $19.87M | -$78.78M | -$86.46M | -$92.83M | -$126.87M | -$69.57M | -$8.90M | -$8.90M | -$4.12M |
| EBITDA? | $20.20M | -$78.44M | -$86.02M | -$92.32M | -$126.67M | -$66.65M | -$29.29M | -$8.89M | -$4.09M |
| Income Before Tax | $22.37M | -$69.68M | -$82.44M | -$91.17M | -$125.60M | -$67.25M | -$35.26M | -$8.93M | -$4.60M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$27,000 | $0 |
| Net Income? | $22.37M | -$69.68M | -$82.44M | -$91.17M | -$125.60M | -$67.25M | -$35.26M | -$8.93M | -$4.60M |
| EPS? | $0.39 | $-1.27 | $-1.88 | $-2.52 | $-3.47 | $-2.04 | $-1.15 | $-0.64 | $-0.64 |
| Diluted EPS? | $0.39 | $-1.27 | $-1.88 | $-2.52 | $-3.47 | $-2.04 | $-1.15 | $-0.64 | $-0.64 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality